Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 3-Year EBITDA Growth Rate is 33.50% as of Mar. 2026, which is 107% above its 10-year median of 16.20. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 692 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 79.62% on this metric.
During the past 12 months, LeMaitre Vascular's average EBITDA Per Share Growth Rate was 31.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 33.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of LeMaitre Vascular was 40.90% per year. The lowest was -67.90% per year. And the median was 16.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
LeMaitre Vascular 3-Year EBITDA Growth Rate Related Terms
LMAT vs PLSE, XRAY, ATRC: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 33.50% mean?
LeMaitre Vascular (LMAT) has a 3-Year EBITDA Growth Rate of 33.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for LeMaitre Vascular and its competitors. This is 107% above median its historical median of 16.20. According to the industry distribution chart, LeMaitre Vascular ranks #141 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 20.4%.
Is LeMaitre Vascular's 3-Year EBITDA Growth Rate too high?
LeMaitre Vascular's current 3-Year EBITDA Growth Rate of 33.50% is 107% above median its 10-year median of 16.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. LeMaitre Vascular's value of 33.50% is 308.5% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #141 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's 3-Year EBITDA Growth Rate compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #141 out of 692 companies for 3-Year EBITDA Growth Rate. This places LeMaitre Vascular in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. LeMaitre Vascular's value of 33.50% is 308.5% above this benchmark. While the company's 10-year median is 16.20 vs. the industry median of 8.20, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current 3-Year EBITDA Growth Rate of 33.50% is 308.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current 3-Year EBITDA Growth Rate is 33.50%, which is 107% above median its own 10-year median of 16.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 33.50%, which is 107% above median its 10-year median of 16.20 and 308.5% above the Medical Devices & Instruments industry median of 8.20. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current 3-Year EBITDA Growth Rate is 33.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
3-Year EBITDA Growth Rate: 33.50% (107% above median its 10-year median of 16.20)
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 308.5% above the Medical Devices & Instruments median (#141 of 692)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
